Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

143.28
+2.491.77%
Post-market: 143.280.00000.00%19:34 EDT
Volume:1.85M
Turnover:265.61M
Market Cap:273.38B
PE:21.66
High:144.28
Open:143.12
Low:142.55
Close:140.79
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:0.90
T/O Rate:0.10%
Dividend:4.67
Dividend Rate:3.26%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.58
PE(LYR):20.04

Loading ...

Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction — ASML, NVS, CASY in Focus

Benzinga Earnings
·
Sep 08

Novartis India Hits Record High on Retina Drugs Distribution Deal, Pfizer Brand Acquisition

Reuters
·
Sep 08

Stocks to Watch: Amgen, Nike, Bloom Energy

Dow Jones
·
Sep 08

Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints

TIPRANKS
·
Sep 08

Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks

Deep News
·
Sep 08

Novartis Might Need More Deals to Deliver Growth Ambitions

Dow Jones
·
Sep 08

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Dow Jones
·
Sep 08

Novartis AG Falls 13% in Pre-Market Trading, DM1 Drug Phase III Clinical Trial Fails to Meet Primary Endpoint

Market Focus
·
Sep 08

Novartis's Latest Trial Setback Sinks Stock

Dow Jones
·
Sep 08

Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell

MT Newswires Live
·
Sep 08

The Inflammation Bet Unravels: Novo And Novartis Both Stumble In Cardiovascular

Bellwether Stocks Movement
·
Sep 08

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Benzinga Earnings
·
Sep 08

Novartis's Latest Trial Failure is Second Pipeline Setback in a Row

Dow Jones
·
Sep 08

Movement Alert|Novartis AG Falls 4.16% Overnight, Phase III Heart Disease Drug Pelacarsen Fails Key Cardiovascular Trial

Market Focus
·
Sep 08

European Equities Remain Flat as Energy Gains Offset by Pharma Slump

Deep News
·
Sep 08

Novartis AG Falls Monday, Underperforms Market

Dow Jones
·
Sep 08

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321

TIPRANKS
·
Sep 07

Citi sees limited immediate downside for Ionis after pelacarsen failure

TIPRANKS
·
Sep 07

BofA sees low single-digit percentage downside for Novartis on pelacarsen miss

TIPRANKS
·
Sep 07

Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial

Dow Jones
·
Sep 07